106 institutions hold shares in Fortress Biotech Inc. (FBIO), with 27.26M shares held by insiders accounting for 29.09% while institutional investors hold 47.68% of the company’s shares. The shares outstanding are 76.09M, and float is at 66.45M with Short Float at 1.85%. Institutions hold 33.81% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Nantahala Capital Management, LLC with over 8.68 million shares valued at $27.52 million. The investor’s holdings represent 9.26% of the FBIO Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 4.72 million shares valued at $14.96 million to account for 5.04% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 4.57 million shares representing 4.88% and valued at over $14.48 million, while Opaleye Management Inc. holds 4.15% of the shares totaling 3.89 million with a market value of $12.32 million.
Fortress Biotech Inc. (NASDAQ: FBIO) is 17.67% higher on its value in year-to-date trading and has touched a low of $1.04 and a high of $4.78 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The FBIO stock was last observed hovering at around $4.11 in the last trading session, with the day’s loss setting it -0.38% off its average median price target of $8.00 for the next 12 months. It is also 82.24% off the consensus price target high of $21.00 offered by 5 analysts, but current levels are 17.11% higher than the price target low of $4.50 for the same period.
Currently trading at $3.73, the stock is 1.04% and 9.44% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.16 million and changing -9.25% at the moment leaves the stock 18.69% off its SMA200. FBIO registered 45.14% gain for a year compared to 6-month loss of 2.19%. The firm has a 50-day simple moving average (SMA 50) of $3.5858 and a 200-day simple moving average (SMA200) of $3.3101.
The stock witnessed a 5.37% gain in the last 1 month and extending the period to 3 months gives it a 35.14%, and is -3.37% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.38% over the week and 6.17% over the month.
Fortress Biotech Inc. (FBIO) has around 93 employees, a market worth around $337.49M and $43.00M in sales. Distance from 52-week low is 258.65% and -21.97% from its 52-week high. The company has generated returns on investments over the last 12 months (-79.70%).
Fortress Biotech Inc. (FBIO) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Fortress Biotech Inc. (FBIO) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Fortress Biotech Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.16 with sales reaching $12.56M over the same period.The EPS is expected to grow by 56.50% this year, but quarterly earnings will post 22.00% year-over-year. Quarterly sales are estimated to grow 12.80% in year-over-year returns.
Fortress Biotech Inc. (FBIO) Insider Activity
A total of 1 insider transactions have happened at Fortress Biotech Inc. (FBIO) in the last six months, with sales accounting for 1 and purchases happening 0 times. The most recent transaction is an insider sale by Hunter Robyn, the company’s Chief Financial Officer. SEC filings show that Hunter Robyn sold 28,450 shares of the company’s common stock on Sep 22 at a price of $4.38 per share for a total of $0.12 million. Following the sale, the insider now owns 0.19 million shares.
Fortress Biotech Inc. disclosed in a document filed with the SEC on Aug 26 that Hoenlein Malcolm (Director) bought a total of 16,667 shares of the company’s common stock. The trade occurred on Aug 26 and was made at $18.00 per share for $0.3 million. Following the transaction, the insider now directly holds 16667.0 shares of the FBIO stock.
Still, SEC filings show that on Aug 26, ROSENWALD LINDSAY A MD (PRESIDENT, CEO & CHAIRMAN) acquired 52,500 shares at an average price of $18.00 for $0.94 million. The insider now directly holds 92,500 shares of Fortress Biotech Inc. (FBIO).
Fortress Biotech Inc. (FBIO): Who are the competitors?
The company’s main competitors (and peers) include Biogen Inc. (BIIB) that is trading -17.12% down over the past 12 months. Sanofi (SNY) is -6.88% down on the 1-year trading charts. Short interest in the company’s stock has fallen -23.58% from the last report on Dec 30, 2020 to stand at a total of 1.52 million short shares sold with a short interest ratio of 1.98.